Clinical trials: Sepsis Bacteremia
Bacteremia
T2Bacteria Panel Pivotal Study
The purpose of this study is to demonstrate the safety and effectiveness of the T2Bacteria Panel by validating the clinical performance (i.e.
- Trial name
- T2Bacteria (NCT02535468)
- Where
- 3 sites in United States
- Volunteers
- 2,430 people
- Sponsor
- T2 Biosystems
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Enterococcal Bacteremia
Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia
Randomized clinical trial to determine the optimal duration of antibiotic treatment for E. Faecalis or E. faecium bacteraemia, following an innovative DOOR / RADAR (Desirability of Outcome Ranking (DOOR) and Response Adjusted for…
- Trial name
- INTENSE (NCT05394298)
- Testing
- Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia., Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
- Where
- 22 sites in Spain
- Volunteers
- 284 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
Infection, Bacteremia
Pharmacodynamic Parameters of Two Different Doses of Cefepime
Pharmacokinetics is the study of the disposition of drugs in the body, while pharmacodynamics considers the interaction of the drug at the site of infection over time.
- Conditions
- Infection, Bacteremia, Pneumonia
- Trial name
- NCT00177736
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Pittsburgh
Neonatal Sepsis, Neonatal Mortality
Prevention of Nosocomial Bacteremia Among Zambian Neonates
The purpose of this study is to estimate the burden of disease, identify risk factors associated with nosocomial bacteremia among neonates and assess the efficacy of low-cost measures targeted to known and suspected nosocomial…
- Trial name
- NCT02386592
- Testing
- Chlorhexidine gluconate (CHG), Hand hygiene (HH), Infection control training
- Where
- Zambia
- Volunteers
- 9,410 people
- Sponsor
- Boston University
Hematologic Malignancy, Leukemia, Acute
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with…
- Conditions
- Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
- Trial name
- SCENE (NCT04710212)
- Testing
- No intervention.
- Where
- 6 sites in United States
- Volunteers
- 168 people
- Sponsor
- Duke University
Endotoxemia
Ethnic Differences in the Inflammatory Response in Systemic Inflammation
The purpose of this study is to investigate putative ethnic differences in the proinflammatory response in human endotoxemia.
- Trial name
- NCT00284869
- Testing
- LPS
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malaria, Bacteremia
Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria
While World Health Organization (WHO) guidelines recommend empirical antibacterial therapy as the standard of care in all African children with severe falciparum malaria, there are fewer data to guide the management of adults…
- Conditions
- Malaria, Bacteremia, Sepsis
- Trial name
- ANTHEM (NCT03224052)
- Where
- Burma
- Volunteers
- 20 people
- Sponsor
- Menzies School of Health Research
Bacteremia, AmpC Beta-lactamase
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Nosocomial bloodstream infections are important causes of morbidity and mortality caused by AmpC beta-lactamase-producing Enterobacteriaceae.
- Trial name
- NCT00414193
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pittsburgh
Healthy Volunteers
Vorapaxar in the Human Endotoxemia Model
Vorapaxar is a recently approved protease activated receptor - 1 (PAR-1) inhibitor. Platelet inhibition may also exert positive results on coagulation activation and may beneficially influence the inflammatory response.
- Trial name
- NCT02875028
- Testing
- Vorapaxar, LPS
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
SIRS, Sepsis
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
The investigators enrolled 144 subjects admitted to ICUs: 60 patients with systemic inflammatory response syndrome (SIRS) and 84 patients with sepsis.
- Conditions
- SIRS, Sepsis, Bacteremia
- Trial name
- NCT01410578
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Chinese PLA General Hospital
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Bacteremia
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.
- Trial name
- NCT00505258
- Testing
- ceftobiprole medocaril
- Sponsor
- Basilea Pharmaceutica
Enterobacteriaceae Infections, Bacteremia
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
To assess the molecular epidemiology, clinical impact, treatment outcome and risk factors for infections caused by Enterobacteriaceae producing ESBLs in Italy in a large multicenter observational survey. SPECIFIC OBJECTIVES 1.
- Conditions
- Enterobacteriaceae Infections, Bacteremia, Pneumonia, Skin Diseases
- Trial name
- NCT00404625
- Testing
- Risk factors for infections due to ESBL+ Enterobacteriaceae, Risk factors for inadequate initial antimicrobial therapy, Overall and 30-day mortality in bad first antibiotic therapy
- Where
- 6 sites in Italy
- Volunteers
- 813 people
- Sponsor
- University of Siena
Healthy, Type 2 Diabetes
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
The aim of the present protocol is to study gene activity in fat and muscle tissue in type 2 diabetics and healthy volunteers after injection of E.
- Conditions
- Healthy, Type 2 Diabetes, Endotoxemia
- Trial name
- NCT00412906
- Testing
- Escherichia Coli Endotoxin
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Aortic Valve Stenosis
The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial
The study is a prospective, crossover, cluster randomized trial in patients undergoing transcatheter aortic valve implantation (TAVI).
- Trial name
- PAPPI (NCT07442357)
- Testing
- Beta-lactam antibiotic with spectrum for Enterococcus faecalis, Cephalosporin
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 1,986 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hypoxia, Endotoxemia
Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia
The objective of the present protocol is to study whether a low level of oxygen in the blood will affect the immune response to as well as cerebral blood flow and metabolism during an infection and, conversely, whether the acute…
- Conditions
- Hypoxia, Endotoxemia, Healthy
- Trial name
- NCT00332267
- Testing
- Endotoxin infusion, Normobaric hypoxia
- Where
- Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet